Amarin Corp Plc (AMRN)

[ziploc_1]

Rose...An upside to an AG is that, in states that require that a generic must be dispensed over a brand, icosapentethyl would gain an advantage.

A downside to an AG is that the price is usually set lower than that of a brand...However Vascepa will have to lower its price anyway in order to sell in EU and ROW including China.The goal for Amarin is to determine a price for Vascepa and their AG so that higher volume will triumph over lower price....This will require some deft handing as to whether and how to market and how to price.

If worked out correctly, EPA could rival statins for sales and pave the way for a statin-EPA combo drug.